Low Percentage of Signal Regulatory Protein α/β(+) Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients

An important goal for personalized treatment is predicting response to a particular therapeutic. A drawback of biological treatment is immunogenicity and the development of antibodies directed against the drug [anti-drug antibodies (ADA)], which are associated with a poorer clinical outcome. Here we...

Descripción completa

Detalles Bibliográficos
Autores principales: Magill, Laura, Adriani, Marsilio, Berthou, Véronique, Chen, Keguan, Gleizes, Aude, Hacein-Bey-Abina, Salima, Hincelin-Mery, Agnes, Mariette, Xavier, Pallardy, Marc, Spindeldreher, Sebastian, Szely, Natacha, Isenberg, David A., Manson, Jessica J., Jury, Elizabeth C., Mauri, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290031/
https://www.ncbi.nlm.nih.gov/pubmed/30568660
http://dx.doi.org/10.3389/fimmu.2018.02865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290031/
https://www.ncbi.nlm.nih.gov/pubmed/30568660
http://dx.doi.org/10.3389/fimmu.2018.02865

Ejemplares similares